Archives
-
VZV Glycoprotein E Mutations and mRNA Vaccine Efficacy
2026-09-12
Cao and colleagues tested whether engineering the carboxyl-terminal trafficking region of varicella-zoster virus glycoprotein E could improve the immune performance of an LNP-formulated mRNA vaccine. Their comparison found that a C-terminal mutant produced consistently strong antibody and T-cell responses, supporting antigen trafficking as a rational design variable while stopping short of proving protective efficacy in infection or reactivation models.
-
Novobiocin Hybrids Against Toxoplasma gondii
2026-09-11
A 2024 Acta Parasitologica study evaluated 12 quinolone–coumarin hybrids derived from fluoroquinolones and novobiocin against Toxoplasma gondii in vitro. QC1, QC3, QC6, and novobiocin produced the most favorable balance between antiparasitic activity and host-cell tolerance, providing a useful lead-selection framework rather than evidence of clinical efficacy.
-
CGP 55845 Hydrochloride in GABAB Assays
2026-09-11
CGP 55845 hydrochloride is a selective GABAB receptor antagonist for separating receptor-driven neurotransmitter release modulation from astrocytic GAT-3 signaling. This article presents a mechanistic assay framework for interpreting synaptic responses, optimizing controls, and assessing exploratory hypoglycemia-related endpoints in vitro.
-
Moesin as a Sepsis Endothelial Injury Biomarker
2026-09-10
Chen et al. identified circulating moesin as a potential indicator of endothelial injury severity in sepsis and linked it mechanistically to ROCK1/MLC and NF-κB signaling. The study integrates patient samples, LPS and cecal ligation and puncture models, and human microvascular endothelial cell experiments to connect biomarker elevation with vascular hyperpermeability.
-
Self-Amplifying RNA Vaccines Improve Influenza Protection
2026-09-10
The reference study shows that self-amplifying RNA can overcome important immunogenicity limits observed with conventional mRNA vaccines against influenza B in mice. Its dose-sparing design, cross-platform comparison, and 20-week antibody follow-up provide a useful framework for evaluating RNA vaccine durability and subtype-specific performance.
-
T7 RNA Polymerase for In Vitro RNA Synthesis
2026-09-09
T7 RNA Polymerase is a recombinant enzyme expressed in E. coli that selectively transcribes DNA templates containing a bacteriophage T7 promoter. Its defined template requirements support in vitro transcription, RNA vaccine production research, and antisense RNA and RNAi research without implying downstream clinical efficacy.
-
Deep Learning for iPSC-CM Cardiotoxicity Screening
2026-09-09
Grafton and colleagues developed a deep-learning, high-content imaging workflow that detects cardiotoxic phenotypes in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) across chemically diverse libraries. The study supports earlier safety triage by converting complex cellular morphology into a scalable score, while also highlighting why mechanistic probes such as Cisapride require complementary electrophysiological validation.
-
Podophyllotoxin Derivative 5p and Multidrug Resistance
2026-09-08
The reference study shows that podophyllotoxin derivative 5p acts through a dual mechanism involving topoisomerase IIα inhibition and impaired microtubule polymerization. Its activity in drug-resistant cancer models, together with effects on transporter expression, mitotic arrest, apoptosis, pyroptosis, and xenograft growth, provides a mechanistic framework for overcoming multidrug resistance.
-
Aurora Kinase A in High-Risk Retinoblastoma
2026-09-08
A 2024 American Journal of Pathology study identifies AURKA overexpression as a frequent feature of retinoblastoma and links it to histopathologic markers of aggressive disease and poor chemotherapy response. By combining patient specimens, cell models, patient-derived material, xenografts, and enucleated tumors, the study provides a translational rationale for testing Aurora A inhibition in high-risk retinoblastoma while emphasizing the need for disease-specific validation.
-
PreScission Protease (PSP): Assay-Ready Purification
2026-09-07
Learn how PreScission Protease (PSP), SKU K1101, supports controlled fusion-tag removal when recombinant proteins are destined for cell viability, proliferation, or cytotoxicity studies. This scenario-based guide covers cleavage-site design, low-temperature handling, data interpretation, and practical vendor-selection criteria.
-
Tobramycin as a Translational Probe of Resistance
2026-09-07
Tobramycin is more than an aminoglycoside antibiotic for routine susceptibility testing: it is a mechanistically informative probe for linking ribosomal inhibition, isolate-level phenotypes, assay design, and antibiotic resistance research. This thought-leadership perspective translates classic clinical-isolate evidence into practical guidance for modern microbiology and translational teams.
-
Chloroquine Diphosphate: Autophagy Research Guide
2026-09-05
Chloroquine Diphosphate is a water-soluble research compound used as a TLR7 and TLR9 inhibitor, autophagy modulator, and cancer research tool. Its cell-type-dependent activity, formulation limits, and distinction between autophagosome accumulation and completed autophagic flux are central to experimental interpretation.
-
Drug-Sensitized Yeast for mTOR Inhibitor Discovery
2026-09-04
Breen and colleagues developed a drug-sensitized Saccharomyces cerevisiae platform that detects TOR inhibitors at substantially lower concentrations than wild-type yeast. The system identified TOR1-dependent activity for Torin1, omipalisib, AZD8055, and aminophylline, while nebivolol and several other tested compounds showed no evidence of TOR inhibition under the assay conditions.
-
Phosphatase Inhibitor Cocktail 1: Workflow Guide
2026-09-04
Protect labile phosphorylation signals from tissue or cell harvest through Western blotting, immunoprecipitation, imaging, and kinase workflows. This guide distinguishes evidence-based tissue interpretation from practical assay recommendations and shows how a 100X DMSO formulation can simplify protein phosphorylation preservation.
-
AG-490 (JAK2/EGFR inhibitor): Assay Guide
2026-09-03
This scenario-based guide shows how AG-490 (JAK2/EGFR inhibitor), SKU A4139, can support interpretable viability, proliferation, and signaling assays. It connects concentration-dependent activity, solvent handling, pathway controls, and vendor-selection criteria to recent evidence on exosomal SNORD52–JAK2/STAT6 signaling in cancer research.